M15-739: An Open-Label Study in Subjects with Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment

Grants and Contracts Details

StatusFinished
Effective start/end date2/28/18 → 1/6/20

Funding

  • AbbVie Incorporated: $46,514.00